What Do The Elevated Protein Levels Mean In My Patients With Myeloma, Amyloidosis, and Related Disorders?

Link to article at PubMed

Am J Med. 2022 Jan 23:S0002-9343(22)00032-8. doi: 10.1016/j.amjmed.2022.01.009. Online ahead of print.


Multiple myeloma, light-chain (AL) amyloidosis and other plasma cell dyscrasias are characterized, in part, by abnormal production of paraproteins that are often responsible for the sequelae of those diseases. These paraproteins are whole or fragmented immunoglobulins produced by clonal antibody-secreting cells (usually plasma cells but occasionally B lymphocytes). Significant heterogeneity exists in the presentation of these diseases, ranging from incidental detection of a monoclonal protein in an asymptomatic patient, to life-threatening manifestations which require urgent diagnostic confirmation and intervention. Successful management of such scenarios requires a fundamental understanding of the laboratory assays at one's disposal, their role in the workup of paraproteinemias, and the interpretation thereof. This review broadly covers these assays and their roles in the diagnosis, prognosis, and management of these diseases.

PMID:35081383 | DOI:10.1016/j.amjmed.2022.01.009

Leave a Reply

Your email address will not be published. Required fields are marked *